Aluvaris

Aluvaris Therapeutics is a biotechnology company focused on the development of advanced therapies for lysosomal storage disorders (LSDs), particularly Pompe disease. The company was founded by Dr. Hung Do, a pioneer in the field of LSDs and former Chief Science Officer of Amicus Therapeutics. Aluvaris utilizes specialized protein engineering and chaperone-based approaches to enhance the delivery and stability of enzyme replacement therapies. In September 2023, the company was acquired by Amicus Therapeutics, integrating its innovative pipeline and expertise into Amicus's leading rare disease portfolio. Its lead program, ALU-001, is designed to provide a more effective treatment option for patients suffering from the debilitating effects of Pompe disease.